Prevention of respiratory syncytial virus infections: Indications for the use of palivizumab and update on the use of RSV-IGIV

Pediatrics

Volumn 102, Issue 5, 1998, Pages 1211-1216

  Halsey, Neal A ^l   Abramson, Jon S ^l   Chesney, P Joan ^l   Fisher, Margaret C ^l   Gerber, Michael A ^l   Marcy, S Michael ^l   Murray, Dennis L ^l   Overturf, Gary D ^l   Prober, Charles G ^l   Saari, Thomas N ^l   Weiner, Leonard B ^l   Whitley, Richard J ^l   Breiman, Robert F ^a   Carolyn Hardegree, M ^b   Hirsch, Anthony ^c   Jacobs, Richard F ^d   MacDonald, Noni E ^e   Orenstein, Walter A ^f   Rabinovich, N Regina ^g   Schwartz, Ben ^f   Peter, Georges ^l   Baker, Carol J ^l   Pickering, Larry K ^l   Meissner, H Cody ^l   Lemons, James A ^l   Blackmon, Lillian R ^l   Kanto Jr , William P ^l   MacDonald, Hugh M ^l   Miller, Carol A ^l   Papile, Lu Ann ^l   Rosenfeld, Warren ^l   Shoemaker, Craig T ^l   Speer, Michael E ^l   Greene Jr , Michael F ^h   Iyasu, Solomon ^f   Johnson, Patricia ⁱ   McMillan, Douglas D ^e   Wright, Linda L ^g   Langer, Jacob C ^k   Stevenson, David K ^j   more..

^a National Vaccine Program Office

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c AAP Council on Pediatrie Practice

^d American Thoracic Society

^e CANADIAN PAEDIATRIC SOCIETY   (Canada)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^g NATIONAL INSTITUTES OF HEALTH   (United States)

^h Amer Coll Obstet Gynecologists

ⁱ American Nurses Association   (United States)

^j Section on Surgery

^k Section on Perinatal Pediatrics

^l NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS VACCINE; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYANOTIC HEART DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; INFANT; INFECTION PREVENTION; INFECTION RISK; INTRAMUSCULAR DRUG ADMINISTRATION; MULTICENTER STUDY; NORMAL HUMAN; PRACTICE GUIDELINE; PREMATURITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT CONTRAINDICATION; VIRUS INFECTION;

EID: 0031729747     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.102.5.1211     Document Type: Review

References (21)

1. American Academy of Pediatrics, Committee on Infectious Diseases. Respiratory syncytial virus immune globulin intravenous: indications for use. Pediatrics. 1997;99:645-650
2. Groothuis JR, Simoes EA, Levin MJ, RSVIG Study Group. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med. 1993;329: 1524-1530
3. Connor E, PREVENT Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics. 1997;99:93-99
4. Simoes EAF, Sondheimer HM, Top FH, et al. Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. J Pediatr. In press
5. Hay JW, Ernst RL, Meissner HC. Respiratory syncytial virus immune globulin: a cost-effectiveness analysis. Am J Man Care. 1996;2: 851-861
6. Johnson S, Oliver C, Prince GA, et al. Development of humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis. 1997;176: 1215-1224
7. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998; 102:531-537
8. American Academy of Pediatrics, Committee on Infectious Diseases. Reassessment of the indications for ribavirin therapy in respiratory syncytial virus infections. Pediatrics. 1996;97:137-140
9. Subramanian SKN, Weisman LE, Rhodes T, et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytia] virus in premature infants and infants with bronchopulmonary dysplasia. Pediatr Infect Dis J. 1998;17:110-115
10. Nachman SA, Navaie-Waliser M, Qureshi MZ. Rehospitalization with respiratory syncytial virus after neonatal intensive care unit discharge: a 3-year follow-up. Pediatrics. 1997;100(6). URL: http://www. pediatrics.org/cgi/content/full/100/6/e8
11. American Academy of Pediatrics. Measles. In: Peter G, ed. 1997 Red Book. Report of the Committee on Infectious Diseases. 24th ed. Elk Grove Village, IL: American Academy of Pediatrics; 1997:353
12. O'Shea TM, Sevick MA, Givner LB. Costs and benefits of respiratory syncytial virus immunoglobulin to prevent hospitalization for lower respiratory tract illness in very low birth weight infants. Pediatr Infect Dis J. 1998;17:587-593
13. Robbins JM, Tilford JM, Jacobs RF, Wheeler JG, Gillaspy SR, Schutze GE. A number-needed-to-treat analysis of the use of respiratory syncytial virus immune globulin to prevent hospitalization. Arch Pediatr Adolesc Med. 1998;152:358-366
14. American Academy of Pediatrics, Committee on Infectious Diseases. Respiratory syncytial virus. In: Peter G, ed. 1997 Red Book. Report of the Committee on Infections Diseases. 24th ed. Elk Grove Village, IL: American Academy of Pediatrics; 1997:446
15. Gilchrist S, Torok TJ, Gary HE Jr, Alexander JP, Anderson LJ. National surveillance for respiratory syncytial virus, United States, J Infect Dis. 1994;170:986-990
16. Torok TJ, Clarke MW, Holman RC, Anderson LJ. Temporal and spatial trends in respiratory syncytial virus activity in the United States, 1990-1996. Presented at RSV After 40 Years: An Anniversary Symposium; November 9-12, 1996; Charleston, SC. Abstract
17. Hall CB, Geiman JM, Douglas RG, Meagher MP. Control of nosocomial respiratory syncytial virus infections. Pediatrics. 1978;62:728-732
18. Groothuis JR, Gutierrez KM, Lauer BA. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. Pediatrics. 1988; 82:199-203
19. Hall CB, Powell KR, MacDonald NE, et al. Respiratory syncytial viral infection in children with compromised immune function. N Engl J Med. 1986;315:77-81
20. MacDonald NE, Hall CB, Suffin SC, Alexson C, Harris PJ, Manning JA. Respiratory syncytial viral infection in infants with congenital heart disease. N Engl J Med. 1982;307:397-400
21. Madge P, Paton JY, McColl JH, Mackie PK. Prospective controlled study of four infection control procedures to prevent nosocomial infection with respiratory syncytial virus. Lancet. 1992;340:1079-1083